Geron Corporation  

(Public, NASDAQ:GERN)   Watch this stock  
Find more results for GERN
3.24
+0.18 (5.88%)
After Hours: 3.25 +0.01 (0.31%)
Dec 26, 7:55PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.05 - 3.24
52 week 1.39 - 5.92
Open 3.06
Vol / Avg. 1.49M/6.54M
Mkt cap 487.08M
P/E     -
Div/yield     -
EPS -0.25
Shares 157.21M
Beta 2.17
Inst. own 46%
Mar 10, 2015
Q4 2014 Geron Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Dec 8, 2014
Geron Analyst and Investor Meeting - Webcast
Dec 3, 2014
Geron Corp at Piper Jaffray Healthcare Conference - Webcast
Nov 19, 2014
Geron Corp at Stifel Healthcare Conference - Webcast
Nov 14, 2014
Geron Corp Announces Global Strategic Collaboration with Janssen Biotech, Inc. Conference Call - Webcast
Nov 3, 2014
Q3 2014 Geron Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -5968.12% -2991.35%
Operating margin -6191.88% -3036.48%
EBITD margin - -2897.58%
Return on average assets -26.09% -45.92%
Return on average equity -27.19% -52.79%
Employees 46 -
CDP Score - -

Address

SUITE 2070, 149 COMMONWEALTH DRIVE
MENLO PARK, CA 94025
United States - Map
+1-650-4737700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase. Geron focuses to develop imetelstat to treat one or more hematologic myeloid malignancies, such as myelofibrosis (MF), myelodysplastic syndromes (MDS), or acute myelogenous leukemia (AML). In October 2013, Geron Corporation announced the closing of the transaction to divest the Company's stem cell assets.

Officers and directors

Hoyoung Huh Ph.D Chairman of the Board
Age: 45
Bio & Compensation  - Reuters
John A. Scarlett M.D. President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Olivia K. Bloom Chief Financial Officer, Executive Vice President - Finance, Treasurer
Age: 44
Bio & Compensation  - Reuters
Stephen N. Rosenfield J.D. Executive Vice President, General Counsel and Corporate Secretary
Age: 63
Bio & Compensation  - Reuters
Andrew J. Grethlein Ph.D. Executive Vice President - Technical Operations
Age: 48
Bio & Compensation  - Reuters
Melissa A. Kelly Behrs Executive Vice President - Portfolio and Alliance Management
Age: 49
Bio & Compensation  - Reuters
Craig C. Parker Executive Vice President - Corporate Development and Scientific Affairs
Bio & Compensation  - Reuters
Susan M. Molineaux Ph.D. Director
Age: 60
Bio & Compensation  - Reuters
Daniel M. Bradbury Independent Director
Bio & Compensation  - Reuters
Karin Eastham CPA Independent Director
Age: 64
Bio & Compensation  - Reuters